OBJECTIVES: To conduct the first prospective randomized controlled trial, evaluating and comparing the effect of medical and surgical treatment of chronic rhinosinusitis (CRS) on quality of life. MATERIALS AND METHODS:Ninety patients with CRS, who remained symptomatic after initial medical treatment with Dexarhinaspray duo and nasal douche, were randomized either to medical or surgical therapy. All patients underwent pre- and post-treatment assessments of the Sinonasal Outcome Test-20 (SNOT-20), and the Short Form 36 Health Survey (SF-36). Each patient had three assessments: before starting the randomized treatment, after six months and finally after one year. RESULTS: Both the medical and surgical treatment of CRS significantly improved almost all the parameters of SNOT and SF-36 (p<0.05), with no significant difference being found between the medical and surgical groups (p>0.05). CONCLUSION: Both maximal medical and surgical therapy of CRS improves the quality of life of CRS patients, providing further evidence that chronic rhinosinusitis should be targeted with maximal medical therapy in the first instance, with surgical treatment being reserved for cases refractory to medical therapy. The presence of nasal polyps does not imply any negative effect on the quality of life after CRS therapy, either medical or surgical.
RCT Entities:
OBJECTIVES: To conduct the first prospective randomized controlled trial, evaluating and comparing the effect of medical and surgical treatment of chronic rhinosinusitis (CRS) on quality of life. MATERIALS AND METHODS: Ninety patients with CRS, who remained symptomatic after initial medical treatment with Dexarhinaspray duo and nasal douche, were randomized either to medical or surgical therapy. All patients underwent pre- and post-treatment assessments of the Sinonasal Outcome Test-20 (SNOT-20), and the Short Form 36 Health Survey (SF-36). Each patient had three assessments: before starting the randomized treatment, after six months and finally after one year. RESULTS: Both the medical and surgical treatment of CRS significantly improved almost all the parameters of SNOT and SF-36 (p<0.05), with no significant difference being found between the medical and surgical groups (p>0.05). CONCLUSION: Both maximal medical and surgical therapy of CRS improves the quality of life of CRSpatients, providing further evidence that chronic rhinosinusitis should be targeted with maximal medical therapy in the first instance, with surgical treatment being reserved for cases refractory to medical therapy. The presence of nasal polyps does not imply any negative effect on the quality of life after CRS therapy, either medical or surgical.
Authors: Agnes S Sundaresan; Annemarie G Hirsch; Amanda J Young; Jonathan Pollak; Bruce K Tan; Robert P Schleimer; Robert C Kern; Thomas L Kennedy; J Scott Greene; Walter F Stewart; Karen Bandeen-Roche; Brian S Schwartz Journal: J Allergy Clin Immunol Pract Date: 2017-11-10
Authors: Anni Koskinen; Matti Penttilä; Jyri Myller; Sari Hammarén-Malmi; Juha Silvola; Tari Haahtela; Maija Hytönen; Sanna Toppila-Salmi Journal: Am J Rhinol Allergy Date: 2012 Nov-Dec Impact factor: 2.467
Authors: A G Hirsch; W F Stewart; A S Sundaresan; A J Young; T L Kennedy; J Scott Greene; W Feng; B K Tan; R P Schleimer; R C Kern; A Lidder; B S Schwartz Journal: Allergy Date: 2016-09-19 Impact factor: 13.146
Authors: Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton Journal: Cochrane Database Syst Rev Date: 2016-04-26
Authors: Lee Yee Chong; Karen Head; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder Journal: Cochrane Database Syst Rev Date: 2016-04-26
Authors: Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder Journal: Cochrane Database Syst Rev Date: 2016-04-26